Prevention and treatment of bleeding by pro-hemostatic treatment strategies

Wien Med Wochenschr. 2003;153(19-20):421-5. doi: 10.1007/s10354-003-0029-9.

Abstract

Pro-hemostatic therapy may achieve an improvement of hemostasis, by amelioration of primary hemostasis, stimulation of fibrin formation or inhibition of fibrinolysis. Pro-hemostatic interventions appear to be effective in reducing peri-operative blood loss and reducing transfusion requirements in specific situations and may be helpful adjuncts in the management of severe spontaneous and post-operative bleeding. The risk of a higher incidence of thrombotic complications associated with the use of pro-hemostatic therapy is unknown but seems not to be very high in clinical practice. There is a need for more systematic and adequately controlled clinical observations to better establish the efficacy and safety of pro-hemostatic interventions.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antifibrinolytic Agents / therapeutic use*
  • Blood Transfusion*
  • Coagulants / therapeutic use*
  • Deamino Arginine Vasopressin / therapeutic use*
  • Factor VIIa / therapeutic use*
  • Hemostasis, Surgical*
  • Humans
  • Postoperative Hemorrhage / drug therapy*
  • Postoperative Hemorrhage / etiology
  • Postoperative Hemorrhage / physiopathology
  • Treatment Outcome

Substances

  • Antifibrinolytic Agents
  • Coagulants
  • Factor VIIa
  • Deamino Arginine Vasopressin